CYAD-101
- Generic Name
- CYAD-101
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
Phase 1
Recruiting
- Conditions
- Unresectable Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Celyad Oncology SA
- Target Recruit Count
- 34
- Registration Number
- NCT04991948
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇧🇪UZ Antwerpen, Edegem, Belgium
🇧🇪UZ Gent, Ghent, Belgium
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
Phase 1
Recruiting
- Conditions
- Unresectable Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Celyad Oncology SA
- Target Recruit Count
- 49
- Registration Number
- NCT03692429
- Locations
- 🇧🇪
UZ Antwerpen, Edegem, Belgium
🇺🇸Moffit Cancer Center, Tampa, Florida, United States
🇧🇪Institut Jules Bordet, Brussels, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath